Confluent Soars 32% on IBM Acquisition Reports, Plus 20 Stocks Making Pre-Market Moves

MarketDash Editorial Team
1 hour ago
Confluent shares jumped over 30% in pre-market trading amid reports that IBM is nearing an $11 billion acquisition deal for the data-infrastructure company. Meanwhile, several other stocks saw significant pre-market volatility, with gainers and losers spanning multiple sectors.

Sometimes the best Monday morning wake-up call is an acquisition rumor with a big number attached. That's exactly what Confluent Inc. (CFLT) shareholders got this morning, as shares rocketed higher in pre-market trading on news that could reshape the data infrastructure landscape.

According to a Sunday report from The Wall Street Journal, International Business Machines Corp (IBM) is in advanced discussions to acquire Confluent for roughly $11 billion. The deal would bring IBM a company that specializes in technology for managing real-time data streams—the kind increasingly used in large artificial intelligence models. In other words, IBM wants a piece of the infrastructure that makes modern AI tick.

The market clearly likes what it's hearing. Confluent shares jumped 31.8% to $30.49 in pre-market trading, reflecting investor optimism that this deal could actually happen.

But Confluent wasn't the only stock making waves before the opening bell. Here's a look at the other big movers in pre-market trading.

The Gainers

Some stocks came out swinging this morning, building on Friday's momentum or reacting to fresh catalysts:

  • Treasure Global Inc (TGL) gained 128% to $58.00 in pre-market trading after already jumping 276% on Friday. Yes, you read those numbers correctly.
  • Cemtrex Inc (CETX) surged 106.8% to $6.35 in pre-market trading. The company announced last month that it entered into a share purchase agreement to acquire Invocon.
  • Top Wealth Group Holding Ltd (TWG) rose 88.5% to $11.35 in pre-market trading after the company issued its fiscal year 2025 profit outlook.
  • Paranovus Entertainment Technology Ltd (PAVS) gained 87.4% to $0.069 in pre-market trading. The stock had already jumped 16% on Friday after the company reported a year-over-year increase in first-half preliminary revenue results.
  • Fulcrum Therapeutics Inc (FULC) rose 40.4% to $12.50 in pre-market trading after announcing initial results from the 20 mg dose cohort of the Phase 1b PIONEER trial of Pociredir in Sickle Cell Disease.
  • MetaVia Inc (MTVA) gained 34% to $10.96 in pre-market trading after gaining 12% on Friday.
  • HWH International Inc (HWH) shares jumped 21.8% to $2.23 in pre-market trading.
  • Ocular Therapeutix Inc (OCUL) gained 11.3% to $14.00 in pre-market trading.
  • Kymera Therapeutics Inc (KYMR) gained 11% to $73.88 in pre-market trading after announcing it will share results from the BroADen Phase 1b clinical trial evaluating KT-621 on Monday, December 8, 2025.

The Losers

Not everyone got good news over the weekend. Several stocks saw meaningful declines before the market even opened:

Pre-market trading often sets the tone for the regular session, but it's worth remembering that lower liquidity can amplify price swings. Still, when you see a 32% pop on acquisition news or triple-digit percentage moves in smaller-cap stocks, it's clear that Monday morning is starting with plenty of action.

Confluent Soars 32% on IBM Acquisition Reports, Plus 20 Stocks Making Pre-Market Moves

MarketDash Editorial Team
1 hour ago
Confluent shares jumped over 30% in pre-market trading amid reports that IBM is nearing an $11 billion acquisition deal for the data-infrastructure company. Meanwhile, several other stocks saw significant pre-market volatility, with gainers and losers spanning multiple sectors.

Sometimes the best Monday morning wake-up call is an acquisition rumor with a big number attached. That's exactly what Confluent Inc. (CFLT) shareholders got this morning, as shares rocketed higher in pre-market trading on news that could reshape the data infrastructure landscape.

According to a Sunday report from The Wall Street Journal, International Business Machines Corp (IBM) is in advanced discussions to acquire Confluent for roughly $11 billion. The deal would bring IBM a company that specializes in technology for managing real-time data streams—the kind increasingly used in large artificial intelligence models. In other words, IBM wants a piece of the infrastructure that makes modern AI tick.

The market clearly likes what it's hearing. Confluent shares jumped 31.8% to $30.49 in pre-market trading, reflecting investor optimism that this deal could actually happen.

But Confluent wasn't the only stock making waves before the opening bell. Here's a look at the other big movers in pre-market trading.

The Gainers

Some stocks came out swinging this morning, building on Friday's momentum or reacting to fresh catalysts:

  • Treasure Global Inc (TGL) gained 128% to $58.00 in pre-market trading after already jumping 276% on Friday. Yes, you read those numbers correctly.
  • Cemtrex Inc (CETX) surged 106.8% to $6.35 in pre-market trading. The company announced last month that it entered into a share purchase agreement to acquire Invocon.
  • Top Wealth Group Holding Ltd (TWG) rose 88.5% to $11.35 in pre-market trading after the company issued its fiscal year 2025 profit outlook.
  • Paranovus Entertainment Technology Ltd (PAVS) gained 87.4% to $0.069 in pre-market trading. The stock had already jumped 16% on Friday after the company reported a year-over-year increase in first-half preliminary revenue results.
  • Fulcrum Therapeutics Inc (FULC) rose 40.4% to $12.50 in pre-market trading after announcing initial results from the 20 mg dose cohort of the Phase 1b PIONEER trial of Pociredir in Sickle Cell Disease.
  • MetaVia Inc (MTVA) gained 34% to $10.96 in pre-market trading after gaining 12% on Friday.
  • HWH International Inc (HWH) shares jumped 21.8% to $2.23 in pre-market trading.
  • Ocular Therapeutix Inc (OCUL) gained 11.3% to $14.00 in pre-market trading.
  • Kymera Therapeutics Inc (KYMR) gained 11% to $73.88 in pre-market trading after announcing it will share results from the BroADen Phase 1b clinical trial evaluating KT-621 on Monday, December 8, 2025.

The Losers

Not everyone got good news over the weekend. Several stocks saw meaningful declines before the market even opened:

Pre-market trading often sets the tone for the regular session, but it's worth remembering that lower liquidity can amplify price swings. Still, when you see a 32% pop on acquisition news or triple-digit percentage moves in smaller-cap stocks, it's clear that Monday morning is starting with plenty of action.